Noura A A Ebrahim

Dr. Noura A A Ebrahim

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
BABudur N. Alanazi
Budur N. Alanazi
HAHoda A. Ahmed
Hoda A. Ahmed
NANuha S. Alharbi
Nuha S. Alharbi
NENoura A A Ebrahim
Noura A A Ebrahim
SSSoliman Soliman
Soliman Soliman
4D printing of smart materials for regenerative medicine applications.

22 April 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
NENoura A A Ebrahim
Noura A A Ebrahim
SSSoliman Soliman
Soliman Soliman
MOMoamen O. Othman
Moamen O. Othman
NTNeveen S. Tahoun
Neveen S. Tahoun

27 January 2021
Verified
Book Chapter
Open access
PDF file
NNNdidi C. Ngwuluka
Ndidi C. Ngwuluka
NANedal Abu-Thabit
Nedal Abu-Thabit
OUOnyinye J. Uwaezuoke
Onyinye J. Uwaezuoke
JEJoan O. Erebor
Joan O. Erebor
MARGARET OKONAWAN ILOMUANYAMARGARET OKONAWAN ILOMUANYA
MARGARET OKONAWAN ILOMUANYA
NENoura A A Ebrahim
Noura A A Ebrahim
Encapsulation, specifically microencapsulation is an old technology with increasing applications in pharmaceutical, agrochemical, environmental, food, and cosmetic spaces. In the past two decades, the advancements in the field of nanotechnology opened the door for applying the encapsulation technology at the nanoscale level. Nanoencapsulation is highly utilized in designing effective drug delivery systems (DDSs) due to the fact that delivery of the encapsulated therapeutic/diagnostic agents to various sites in the human body depends on the size of the nanoparticles. Compared to microencapsulation, nanoencapsulation has superior performance which can improve bioavailability, increase drug solubility, delay or control drug release and enhance active/passive targeting of bioactive agents to the sites of action. Encapsulation, either micro- or nanoencapsulation is employed for the conventional pharmaceuticals, biopharmaceuticals, biologics, or bioactive drugs from natural sources as well as for diagnostics such as biomarkers. The outcome of any encapsulation process depends on the technique employed and the encapsulating material. This chapter discusses in details (1) various physical, mechanical, thermal, chemical, and physicochemical encapsulation techniques, (2) types and classifications of natural polymers (polysaccharides, proteins, and lipids) as safer, biocompatible and biodegradable encapsulating materials, and (3) the recent advances in using lipids for therapeutic and diagnostic applications. Polysaccharides and proteins are covered in the second part of this chapter.

5 June 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NENoura A A Ebrahim
Noura A A Ebrahim
MHMustafa A. Hussein
Mustafa A. Hussein
MSMohamed Emam Sobeih
Mohamed Emam Sobeih
NANancy H. Amin
Nancy H. Amin
Background: Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior and limited treatment options, primarily due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TROP-2, a transmembrane glycoprotein, exhibits notable overexpression in a spectrum of highly aggressive cancers including pancreatic, gastric, and ovarian cancers. This overexpression has established TROP-2 as a key prognostic biomarker and a promising target for therapeutic intervention. Objective: This research examines the correlation between TROP-2 expression and clinicopathological features in TNBC, assessing its utility as both a prognostic indicator and a candidate for targeted precision therapy. Methods: Retrospective analysis of 80 TNBC patient samples from January 2016 to December 2019 at the National Cancer Institute, Cairo University, Egypt was carried out. Formalin-fixed, paraffin-embedded (FFPE) tissues were evaluated for TROP-2 expression using immunohistochemistry. Clinical and pathological data including patient demographics, tumor characteristics, treatment modalities, and survival outcomes were gathered. TROP-2 expression was correlated with clinicopathological variables and survival metrics (overall survival, OS; disease-free survival, DFS). Results: A high expression of TROP-2 was observed in 78% of cases, exhibiting notable heterogeneity in intensity, proportion of positive cells, and H-score. TROP-2 expression correlated with larger tumor dimensions and advanced nodal involvement, suggesting its contribution to tumor aggressiveness. Elevated TROP-2 intensity and H-scores were significantly associated with poorer overall survival (OS; p = 0.003 and p = 0.007, respectively) and disease-free survival (DFS; p = 0.002 for both). Multivariate analysis revealed TROP-2 intensity, percentage of expression, and H-score as independent predictors of OS (p = 0.02, 0.001, and 0.012, respectively). Similarly, these variables were identified as independent prognostic indicators for DFS, with significant p-values of 0.002, 0.009, and 0.002. Conclusions: Our research validates TROP-2 overexpression as an essential prognostic marker and a potential therapeutic target in TNBC. The results endorse the use of TROP-2 expression levels for patient categorization, thereby advancing the implementation of personalized treatment strategies and accelerating the progression towards precision oncology.

19 February 2025 in Biomedical Materials & Devices
Verified
Journal Article
Closed access
PDF file
NENoura A A Ebrahim
Noura A A Ebrahim
SSSoliman M. A. Soliman
Soliman M. A. Soliman